Condition: Thymus Carcinoma · Sponsor: Jonsson Comprehensive Cancer Center
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This description comes directly from the study's public registry record.
Kim Nahyun · 310-633-8400 · NSKim@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| University of California at Davis (UCD) | Davis, California, United States | Not Yet Recruiting |
| University of California at Irvine (UCI) | Irvine, California, United States | Not Yet Recruiting |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California at San Francisco (UCSF) | San Francisco, California, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06980077